Abstract CN24
Background
Our study of the level and structure of mortality of the population of the Andijan region from malignant neoplasms for the period 2016-2018 will allow us to further develop a plan of measures aimed at improving the organization of medical care for cancer patients and guaranteeing high quality.
Methods
The analysis of morbidity and mortality of malignant neoplasms was carried out according to the data contained in the annual reporting form No. 007 of the statistical department of the regional branch of the COR of the Republic of Uzbekistan.
Results
Among the main causes of mortality from malignant neoplasms in the female population of the Andijan region in 2016, breast cancer ranked 1st – 9.8/100 000 (30%), in 2nd place, were cervical tumors – 5.9/100 000 (17.9%), in 3rd place was stomach cancer – 3.2/100 000 female population (9.8 %). In 2017, the mortality rate of the entire population of the Andijan region from malignant neoplasms was 35.9/100 000 of the population. Among the leading causes of mortality from malignant neoplasms of the female population of the Andijan region in 2017, breast cancer was in the 1st place – 6.6/100 000 (9.2% of all malignant neoplasms that caused the death of women), in 2nd place tumors of the cervix, turned out to be 5.0/100 000 (7.0%), in 3rd place was esophageal cancer – 2.3/100 000 of the female population (3.2%). In 2018, the mortality rate of the entire population of the Andijan region from malignant neoplasms was 33.7/100 000 (6.1% lower than in 2017) of the population. Among the main causes of death from malignant neoplasms of the female population of the Andijan region in 2018, breast cancer ranked 1st – 7.2/100 000 (19.5%), in 2nd place were cervical tumors – 5.7/100 000 (15.5%), in 3rd place was stomach cancer – 3.2/100 000 of the female population (8.8%).
Conclusions
Based on the results obtained, it can be concluded that the incidence of diseases with “top” nosology among the female population of the Andijan region is increasing annually. On the one hand, this is negative, but mortality from this disease decreases annually, as a result of the correct management and implementation of screening programs aimed at early detection of leading tumors in women.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Andijan State Medical Institute.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.